JP2003518115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003518115A5 JP2003518115A5 JP2001547093A JP2001547093A JP2003518115A5 JP 2003518115 A5 JP2003518115 A5 JP 2003518115A5 JP 2001547093 A JP2001547093 A JP 2001547093A JP 2001547093 A JP2001547093 A JP 2001547093A JP 2003518115 A5 JP2003518115 A5 JP 2003518115A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- carbon atoms
- chirally pure
- isomer
- oxadiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims 22
- -1 Nitro, cyano, hydroxy, tert-butyl Chemical group 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- 125000005293 bicycloalkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 4
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical group N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 2
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- RSZRNOGQARDDFO-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-4-methylisoindole-1,3-dione Chemical compound COC1=CC=C(C(CC=2OC=NN=2)N2C(C3=C(C)C=CC=C3C2=O)=O)C=C1OC1CCCC1 RSZRNOGQARDDFO-UHFFFAOYSA-N 0.000 claims 1
- VDLRFAGUSUZOBF-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-4-methylisoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=C(C)C=CC=C3C2=O)=O)=C1 VDLRFAGUSUZOBF-UHFFFAOYSA-N 0.000 claims 1
- BDWWTCKFRDSMRX-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]benzo[e]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=C4C=CC=CC4=CC=C3C2=O)=O)=C1 BDWWTCKFRDSMRX-UHFFFAOYSA-N 0.000 claims 1
- UOQMOWITZGWSCW-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]isoindole-1,3-dione Chemical group C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=CC=CC=C3C2=O)=O)=C1 UOQMOWITZGWSCW-UHFFFAOYSA-N 0.000 claims 1
- DCXXFNKDFYYSDI-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC(C)=NN=2)N2C(C3=CC=CC=C3C2)=O)=C1 DCXXFNKDFYYSDI-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 208000020670 canker sore Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000005588 protonation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/470,203 | 1999-12-21 | ||
| US09/470,203 US6326388B1 (en) | 1999-12-21 | 1999-12-21 | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| PCT/US2000/034457 WO2001046183A1 (en) | 1999-12-21 | 2000-12-19 | SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003518115A JP2003518115A (ja) | 2003-06-03 |
| JP2003518115A5 true JP2003518115A5 (https=) | 2005-06-09 |
| JP4806151B2 JP4806151B2 (ja) | 2011-11-02 |
Family
ID=23866662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001547093A Expired - Fee Related JP4806151B2 (ja) | 1999-12-21 | 2000-12-19 | 置換１，３，４−オキサジアゾールおよびＴＮＦαレベルの減少方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6326388B1 (https=) |
| EP (3) | EP1462449B9 (https=) |
| JP (1) | JP4806151B2 (https=) |
| KR (2) | KR100832499B1 (https=) |
| CN (1) | CN1413211A (https=) |
| AT (3) | ATE489996T1 (https=) |
| AU (1) | AU782168B2 (https=) |
| CA (1) | CA2394615C (https=) |
| DE (3) | DE60042902D1 (https=) |
| ES (3) | ES2233488T3 (https=) |
| FI (1) | FI121708B (https=) |
| HK (1) | HK1050522B (https=) |
| MX (1) | MXPA02006084A (https=) |
| NO (1) | NO323449B1 (https=) |
| NZ (1) | NZ529009A (https=) |
| PT (1) | PT1242413E (https=) |
| TW (2) | TW200733960A (https=) |
| WO (1) | WO2001046183A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| RU2188819C2 (ru) * | 1996-08-12 | 2002-09-10 | Селджин Корпорейшн | НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB |
| AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
| EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| KR20050043923A (ko) * | 2002-09-16 | 2005-05-11 | 알콘 매뉴팩츄어링, 리미티드 | 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도 |
| JP2006510606A (ja) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 |
| US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| NZ540384A (en) * | 2002-11-06 | 2008-06-30 | Celgene Corp | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| EP1567154A4 (en) | 2002-11-06 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES |
| WO2004054501A2 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| JP2006510617A (ja) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物 |
| DE60330187D1 (de) * | 2002-12-30 | 2009-12-31 | Celgene Corp | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen |
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| WO2005046593A2 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
| AU2004293443A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc. | Indazole Compounds and methods of use thereof as protein kinase inhibitors |
| EP1744748A4 (en) * | 2004-04-14 | 2009-08-12 | Celgene Corp | METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES |
| US20050239867A1 (en) * | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| ZA200704251B (en) * | 2004-10-28 | 2008-11-26 | Celgene Corp | Methods and compositions using PDE4 modulators for treatment and management of central nervous injury |
| US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| EP2296683B1 (en) * | 2008-06-03 | 2017-01-25 | University Of Rochester | AvrA PROTEIN FOR TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF |
| US8563580B2 (en) | 2008-09-23 | 2013-10-22 | Georgetown University | Flavivirus inhibitors and methods for their use |
| WO2010039545A2 (en) * | 2008-09-23 | 2010-04-08 | Georgetown University | 1,2-benzisothiazolinone and isoindolinone derivatives |
| PE20120580A1 (es) | 2009-02-10 | 2012-05-23 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
| ES2739973T3 (es) * | 2009-05-29 | 2020-02-05 | Merck Sharp & Dohme | Inhibidores de PDE10 radiomarcados |
| MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
| US20110318741A1 (en) | 2010-06-15 | 2011-12-29 | Schafer Peter H | Biomarkers for the treatment of psoriasis |
| US9428472B2 (en) | 2011-08-16 | 2016-08-30 | Georgetown University | Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives |
| US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| JP2018527302A (ja) | 2015-06-26 | 2018-09-20 | セルジーン コーポレイション | 免疫調節化合物を用いたカポジ肉腫またはｋｓｈｖ誘発性リンパ腫の治療方法、及びバイオマーカーの使用 |
| WO2017070291A1 (en) | 2015-10-21 | 2017-04-27 | Celgene Corporation | Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris) |
| CN107698484B (zh) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | 一种来那度胺的衍生物的制备方法与应用 |
| CN110386893B (zh) | 2018-04-17 | 2025-07-11 | 天津合美医药科技有限公司 | 异吲哚衍生物 |
| WO2020060963A1 (en) * | 2018-09-18 | 2020-03-26 | Alxerion Biotech Corp. | 1, 3, 4-oxadiazole derivatives and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
| SE434638B (sv) | 1980-06-06 | 1984-08-06 | Lekemedelsfabriken Medica Ab | Nya terapeutiska verdefulla taurinderivat och deras framstellning |
| US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| SK280193B6 (sk) * | 1992-04-07 | 1999-09-10 | Pfizer Inc. | Indolové deriváty predstavujúce 5-ht1 agonisty, fa |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| FR2712886B1 (fr) * | 1993-11-26 | 1996-01-05 | Synthelabo | Dérivés de 1,3,4-oxadiazol-2(3H)-one, leur préparation et leur application en thérapeutique. |
| JPH07278125A (ja) * | 1994-03-31 | 1995-10-24 | Nippon Chemiphar Co Ltd | アルキレンジアミン誘導体 |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| NZ305940A (en) | 1995-07-26 | 1999-05-28 | Pfizer | N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| US5670526A (en) * | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
| JP4358908B2 (ja) | 1996-01-02 | 2009-11-04 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 置換（アリール、ヘテロアリール、アリールメチル又はヘテロアリールメチル）ヒドロキサム酸化合物 |
| RU2188819C2 (ru) | 1996-08-12 | 2002-09-10 | Селджин Корпорейшн | НОВЫЕ ИММУНОТЕРАПЕВТИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ ФДЭ, TNFα И NFκB |
| JP2921760B2 (ja) * | 1997-05-21 | 1999-07-19 | 日本たばこ産業株式会社 | フタルイミド誘導体及びそれら誘導体を含んでなる医薬 |
| EP1049693A1 (en) * | 1997-11-26 | 2000-11-08 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS |
| US6034113A (en) * | 1998-01-29 | 2000-03-07 | Bristol-Myers Squibb Company | Derivatives of 1,3,4-oxadiazolone |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
-
1999
- 1999-12-21 US US09/470,203 patent/US6326388B1/en not_active Expired - Lifetime
-
2000
- 2000-12-11 TW TW095138294A patent/TW200733960A/zh unknown
- 2000-12-11 TW TW089125923A patent/TWI280961B/zh not_active IP Right Cessation
- 2000-12-19 DE DE60042902T patent/DE60042902D1/de not_active Expired - Lifetime
- 2000-12-19 NZ NZ529009A patent/NZ529009A/en not_active IP Right Cessation
- 2000-12-19 ES ES00986568T patent/ES2233488T3/es not_active Expired - Lifetime
- 2000-12-19 DE DE60016029T patent/DE60016029T2/de not_active Expired - Lifetime
- 2000-12-19 EP EP04003830A patent/EP1462449B9/en not_active Expired - Lifetime
- 2000-12-19 KR KR1020027007983A patent/KR100832499B1/ko not_active Expired - Fee Related
- 2000-12-19 WO PCT/US2000/034457 patent/WO2001046183A1/en not_active Ceased
- 2000-12-19 CA CA002394615A patent/CA2394615C/en not_active Expired - Fee Related
- 2000-12-19 AT AT04020108T patent/ATE489996T1/de not_active IP Right Cessation
- 2000-12-19 ES ES04003830T patent/ES2333011T3/es not_active Expired - Lifetime
- 2000-12-19 MX MXPA02006084A patent/MXPA02006084A/es active IP Right Grant
- 2000-12-19 EP EP00986568A patent/EP1242413B1/en not_active Expired - Lifetime
- 2000-12-19 EP EP04020108A patent/EP1510518B1/en not_active Expired - Lifetime
- 2000-12-19 JP JP2001547093A patent/JP4806151B2/ja not_active Expired - Fee Related
- 2000-12-19 KR KR1020077008998A patent/KR20070049688A/ko not_active Ceased
- 2000-12-19 AT AT04003830T patent/ATE441644T1/de not_active IP Right Cessation
- 2000-12-19 PT PT00986568T patent/PT1242413E/pt unknown
- 2000-12-19 CN CN00817536A patent/CN1413211A/zh active Pending
- 2000-12-19 ES ES04020108T patent/ES2356238T3/es not_active Expired - Lifetime
- 2000-12-19 DE DE60045320T patent/DE60045320D1/de not_active Expired - Lifetime
- 2000-12-19 HK HK03101117.3A patent/HK1050522B/en not_active IP Right Cessation
- 2000-12-19 AT AT00986568T patent/ATE282612T1/de active
- 2000-12-19 AU AU22785/01A patent/AU782168B2/en not_active Ceased
-
2002
- 2002-06-18 NO NO20022937A patent/NO323449B1/no not_active IP Right Cessation
- 2002-06-19 FI FI20021192A patent/FI121708B/fi not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003518115A5 (https=) | ||
| JP2003518060A5 (https=) | ||
| CA2394615A1 (en) | Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels | |
| CN100372836C (zh) | 新的免疫治疗剂亚酰胺/酰胺类 | |
| FI119841B (fi) | Substituoituja alkanohydroksaamihappoja ja menetelmä TNFalfa tasojen laskemiseksi | |
| ES2278467T3 (es) | Fenetilsulfonas sustituidas y metodo para reducir los niveles de tnf-alfa y pde-iv. | |
| ES2282147T3 (es) | Derivados de isoindolina farmaceuticamente activos. | |
| JP2001526269A5 (https=) | ||
| JP2002506861A5 (https=) | ||
| CA2321920A1 (en) | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | |
| JP2005535586A5 (https=) | ||
| JP2004535447A5 (https=) | ||
| JP2005537248A5 (https=) | ||
| JP2004509113A5 (https=) | ||
| JP2001526222A5 (https=) | ||
| CN115209900A (zh) | 用于预防或治疗其中存在kras突变和活化ron的癌症的药物组合物 | |
| JP2006525944A5 (https=) | ||
| JP2004529925A5 (https=) | ||
| JP2002518395A5 (https=) | ||
| HRP20090468T1 (hr) | Urea antagonisti p2y1 receptora korisni u liječenju trombotičkih stanja | |
| CN1255059A (zh) | 治疗狗的疼痛和炎症的cox－2选择性咔洛芬 | |
| RU2009131454A (ru) | Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств | |
| RU2008151762A (ru) | Adlh-2 ингибиторы для лечения аддикции | |
| WO2005037791A1 (en) | Compositions and methods for viral inhibition | |
| JP2006510606A5 (https=) |